Methylglyoxal (MGO) Lowering Cocktail to Reduce Appetite in Obese Individuals
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Mechanisms that drive addiction to sugar rich foods are a major driving factor in the
pathogenesis of obesity, which has become one of the most significant health care burdens.
The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are
poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced
Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The
investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of
alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a
multimodal effect influencing many pathways related to aging including calorie restriction.
Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in
the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of
C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these
results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of
compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to
lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower
food intake.